Ex vivo JAK and TNF inhibitor-modulated immune signatures guide first-line therapy selection in rheumatoid arthritis. (PubMed, Biomark Res) - Oct 23, 2026 - "Ex vivo-derived JAKi- and TNFi-associated immune-related protein signatures, integrated within a machine-learning framework, showed moderate discriminatory ability for treatment-specific remission patterns in b/tsDMARD-naïve RA and, together with complementary evidence of reduced synovial lining thickness in remission achievers, support further investigation of biomarker-informed selection between JAKi and TNFi as first targeted therapies."
Journal • Preclinical • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology
|
|
Alejandro Escudero-Contreras; Beatriz Malvar-Fernández; Carlos Pérez-Sánchez; Chary López-Pedrera; Christian Merlo; Concepción Aranda-Varela; Desireé Ruiz-Vilchez; Elena Moreno-Caño; Ismael Sanchez-Pareja; Jerusalén Calvo; Laura Muñoz-Barrera; Lourdes Ladehesa; Lydia Formanti; M Carmen Ábalos-Aguilera; Marta E Alarcón-Riquelme; Mª Angeles Aguirre; Nuria Barbarroja; Pilar Font; Rafaela Ortega-Castro; Sagrario Corrales; Samuel Garcia; Tomás Cerdó
|